Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Capital Expenditures: 2012-2025

Historic Capital Expenditures for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $1.6 million.

  • Agios Pharmaceuticals' Capital Expenditures rose 271.12% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 337.29%. This contributed to the annual value of $1.7 million for FY2024, which is 68.67% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Capital Expenditures stood at $1.6 million, which was up 77.71% from $875,000 recorded in Q2 2025.
  • Agios Pharmaceuticals' Capital Expenditures' 5-year high stood at $4.5 million during Q4 2021, with a 5-year trough of -$22,000 in Q3 2021.
  • In the last 3 years, Agios Pharmaceuticals' Capital Expenditures had a median value of $399,000 in 2023 and averaged $534,545.
  • Per our database at Business Quant, Agios Pharmaceuticals' Capital Expenditures tumbled by 100.42% in 2021 and then spiked by 5,366.67% in 2024.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Capital Expenditures stood at $4.5 million in 2021, then slumped by 97.49% to $113,000 in 2022, then surged by 107.08% to $234,000 in 2023, then spiked by 313.25% to $967,000 in 2024, then spiked by 271.12% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $875,000 for Q2 2025, and $766,000 during Q1 2025.